Shrink Nanotechnologies, Inc. ("Shrink") (OTCBB:INKN), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications for its stem cell research and drug discovery tool StemDisc™ have been filed.
“Embryonic stem cell research could help us understand, and possibly cure, some of our most devastating diseases and conditions.”
StemDisc is Shrink's latest bioscience application of its proprietary, patent-pending, advanced plastic material called NanoShrink™. StemDisc offers a low cost, flexible and cost effective solution for biotech researchers to conduct experiments for (i) drug discovery, (ii) regenerative medicine (ii) and cancer research, among others. Following a lift on the ban to federally fund stem cell research, President Obama said in his speech on March 9, 2009, "Embryonic stem cell research could help us understand, and possibly cure, some of our most devastating diseases and conditions."
"Biotech researchers, pharmaceutical companies and universities worldwide are seeking the 'picks' and 'shovels' for this generation's stem cell 'gold rush.' StemDisc provides those tools to accelerate cell culturing at a lower cost compared to existing protocols. Based on our relationships with biotech innovators and leading researchers, we estimate the stem cell research market is presently valued at $2-4 Billion globally, with a projected compound annual growth rate of 20%. Our patent filing on StemDisc is a part of developing an extensive intellectual property position for a number of biomedical research technologies and tools we intend to address publicly in the near future," said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.
Researchers discover mechanism affecting splicing process in retinal cells